Nasdaq Thrx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq thrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Thrx Today - Breaking & Trending Today

MoonLake Immunotherapeutics (NASDAQ:MLTX) versus Theseus Pharmaceuticals (NASDAQ:THRX) Financial Review

Theseus Pharmaceuticals (NASDAQ:THRX – Get Free Report) and MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends. Insider and Institutional Ownership 91.1% of Theseus Pharmaceuticals […] ....

United Kingdom , United States , Moonlake Immunotherapeutics , Moonlake Immunotherapeutic , News Ratings For Theseus Pharmaceuticals Daily , Theseus Pharmaceuticals Inc , Theseus Pharmaceuticals , Get Free Report , Given Theseus Pharmaceutical , Theseus Pharmaceuticals Daily , Nasdaq Thrx , Stock Comparison , Stock Analysis ,

Theseus Pharmaceuticals (NASDAQ:THRX) Trading Down 0.4%

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX – Get Free Report)’s share price traded down 0.4% during trading on Tuesday . The stock traded as low as $2.27 and last traded at $2.30. 105,762 shares changed hands during trading, a decline of 68% from the average session volume of 335,687 shares. The stock had previously closed at $2.31. […] ....

Stifel Nicolaus , Theseus Pharmaceuticals Price Performance , Institutional Investors Weigh In On Theseus Pharmaceuticals , Cantor Fitzgerald , Denali Advisors , News Ratings For Theseus Pharmaceuticals Daily , Theseus Pharmaceuticals Inc , Needham Company , Affinity Asset Advisors , Jump Financial , Fairmount Funds Management , Theseus Pharmaceuticals , Get Free Report , Capital Management , Asset Advisors , Funds Management , Theseus Pharmaceuticals Daily , Nasdaq Thrx ,

Insider Buying: Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) Director Buys 479,932 Shares of Stock

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX – Get Free Report) Director Carl L. Gordon bought 479,932 shares of the company’s stock in a transaction on Monday, July 17th. The shares were bought at an average price of $3.05 per share, for a total transaction of $1,463,792.60. Following the completion of the acquisition, the director now directly owns […] ....

United States , Stifel Nicolaus , Carll Gordon , Cantor Fitzgerald , Needham Company , Barclays Plc , Theseus Pharmaceuticals , News Ratings For Theseus Pharmaceuticals Daily , Theseus Pharmaceuticals Inc , Hedge Funds Weigh In On Theseus Pharmaceuticals , Theseus Pharmaceuticals Price Performance , American International Group Inc , Tower Research Capital , Jpmorgan Chase Co , Get Free Report , Director Carl , Research Capital , International Group , Theseus Pharmaceuticals Daily , Nasdaq Thrx , Insider Trading , Nsider Trades ,